TIDMMTPH
Midatech Pharma PLC
21 September 2016
21 September 2016
Midatech Pharma PLC
("Midatech" or the "Company")
Midatech Pharma US Announces Partnership with R-Pharm US to
Co-promote Zuplenz(R) (ondansetron) oral soluble film and Oravig(R)
(miconazole) orally-dissolving buccal tablet
Partnership provides additional reach and frequency within the
oncology market
Deal broadens Zuplenz and Oravig account call points
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international
specialty pharmaceutical company focused on commercialising and
developing products in oncology, immunology and other therapeutic
areas, today announced that its US subsidiary, Midatech Pharma US,
has finalised a co-promotion agreement with R-Pharm US LLC
providing additional reach and frequency for the promotion of
Zuplenz and Oravig to oncology accounts across the US.
Under the terms of the agreement, R-Pharm will promote Zuplenz
and Oravig in accounts that are not currently in the Midatech
Pharma US call universe as well as provide additional promotion in
accounts where Midatech currently markets its oncology supportive
care product portfolio.
David R. Benharris, President of Midatech Pharma US, said: "We
are extremely excited to add a valued partner in R-Pharm, who can
provide additional promotional reach into new accounts as well as
supplemental frequency to additional call points in our targeted
offices. Our products, as with many pharmaceuticals products, are
detail sensitive. The partnership with R-Pharm provides an enriched
share of voice to further bolster our ongoing commercial efforts
for both Zuplenz and Oravig."
Mark Pavoa, President and Chief Executive Officer of R-Pharm US,
said: "Zuplenz and Oravig are complementary to our oncology
franchise, which includes Ixempra(R) . Cancer patients and
treatment teams face many challenges as they battle the disease,
and we are proud to represent these two additional potential
solutions."
Demetrios Kydonieus, President and Chief Business Officer of
R-Pharm US, commented: "Adding Zuplenz and Oravig to our existing
portfolio allows us to leverage our commercialisation investment
and to increase the value we bring to patients and the medical
offices we serve."
Zuplenz is the only oral soluble film formulation of the 5-HT3
receptor antagonist ondansetron, indicated for the prevention of
nausea and vomiting associated with the use of highly and
moderately emetogenic cancer chemotherapies, radiotherapy, and in
postoperative patients.
Oravig is the only once-daily local therapy available for
treatment of oral thrush in adults. All other currently marketed,
localised therapies for oral thrush require patients to
take/administer their treatment a minimum of four times daily.
R-Pharm will begin promoting both Oravig and Zuplenz in January
of 2017.
- ENDS -
For more information, please contact:
Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance
Freddy Crossley / Atholl Tweedie / Duncan Monteith
Corporate Broking
Tom Salvesen
Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik
Thys
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on oncology and other therapeutic areas with a commercial
platform and four marketed products in the US. Midatech's strategy
is to develop products in-house in oncology and with partners in
other indications, and to accelerate growth organically and through
strategic acquisitions. The Company's R&D activities are
supported by two breakthrough drug delivery technologies. The
Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in
four countries. For further company information see:
www.midatechpharma.com
About R-Pharm US
R-Pharm US is a fully integrated specialty pharmaceutical
company focused on the development and commercialization of
medicines to treat cancer and chronic immune diseases. For further
company information see: www.rpharm-us.com
For full prescribing information, including approve indications,
potential side effects and other warnings on Ixempra, please visit
www.ixempra.com
Forward-Looking Statement
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of legislation in
the United Kingdom and/or United States. Such forward-looking
statements include, but are not limited to, statements regarding
the ability of Midatech to successfully commercialise any of its
products. Any forward-looking statements are based on currently
available competitive, financial and economic data together with
management's views and assumptions regarding future events and
business performance as of the time the statements are made and are
subject to risks and uncertainties. We wish to caution you that
there are some known and unknown factors that could cause actual
results to differ materially from any future results, performance
or achievements expressed or implied by such forward-looking
statements. For a complete discussion of Risk Factors, please refer
to the Company's Form 20-F Annual Report filing to be found at
www.midatechpharma.com/investors/financial-reports.html
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFBLLLQKFFBBX
(END) Dow Jones Newswires
September 21, 2016 02:01 ET (06:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024